Active Surveillance of Antimicrobial Resistance and Carbapenemase-Encoding Genes According to Sites of Care and Age Groups in Mexico: Results from the INVIFAR Network.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Combined therapy with nebulized and intravenous colistin for the treatment of multidrug resistance pneumonia in burn patients: experience from a third referral burn care center in Mexico City.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
   Article
2. Shift of antibiotic resistance after the COVID-19 pandemic: results from the INVIFAR Network.JAC-antimicrobial resistance · 2026
   Article
3. Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico.Scientific reports · 2026
   Article
4. The threat of multidrug-resistant microorganisms: active surveillance of key antimicrobial resistant pathogens in 2025 - a report from the INVIFAR network.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
   Article
5. Prevalence of Carbapenem-Resistant Gram-Negative Bacilli from Intensive Care Units from Latin America and the Caribbean: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026
   Review
6. Phylogenomic and phenotypic profiling of carbapenem-resistantMicrobial genomics · 2026
   Article
7. Molecular Epidemiology of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
   Article
8. Emergence of a methicillin-susceptibleFrontiers in cellular and infection microbiology · 2026
   Article
9. Resistance Landscape and Clonal Dynamics of ESKAPE Pathogens in Bloodstream Infections: A Multicenter Study from Mexico.Pathogens (Basel, Switzerland) · 2025
   Article
10. Prevalence of difficult-to-treat resistance in ESKAPE pathogens in a third level hospital in Mexico.Infection prevention in practice · 2025
    Article
11. The ongoing antibiotic resistance and carbapenemase encoding genotypes surveillance. The first quarter report of the INVIFAR network for 2024.PloS one · 2025
    Article
12. Profile of bacterial resistance in emergency wards, non-intensive care unit areas, and intensive care units in Mexican hospitals with the antimicrobial stewardship program.IJID regions · 2024
    Article
13. Rapid Detection of Carbapenemases Using NG-TestAntibiotics (Basel, Switzerland) · 2024
    Article
14. A Point Prevalence Survey of Antimicrobial Use in Second-Level Mexican Hospitals: A Multicenter Study.Antibiotics (Basel, Switzerland) · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

51 authors.

Funding

Abstract

Indexed as